NEW YORK (AP) — A former executive at pharmaceutical company Mylan has pleaded guilty to insider trading in the company’s securities, the Justice Department said Friday.
The department said Dayakar Mallu, 51, of Orlando, Florida, worked with another executive at Mylan to make trades between 2017 and 2019 based on nonpublic information about Mylan. The information ranged from corporate earnings, to new drug approvals, to Mylan's eventual merger with a division of Pfizer.
At the time, Mallu was Mylan’s vice president of global operations information technology. The Justice Department listed the other Mylan executive as an unnamed co-conspirator.
Mallu realized net profits and losses avoided of more than $4.2 million, the department said. He allegedly shared the trading profits with the other Mylan insider through payments routed through India. He also he sent false information to his tax preparer, the Justice Department said.
Mallu is scheduled to be sentenced in January and faces a maximum 25 years for the insider trading and three years for the tax offense. He also consented to charges from the Securities and Exchange Commission that, if approved by a judge, would bar him from acting as the officer or director of a public company.
Mylan merged in late 2020 with Pfizer division Upjohn to form a new drug company known as Viatris.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
Companies Mentioned in This Article
Compare These Stocks Add These Stocks to My Watchlist
